GLP-1 receptor agonists actively revolutionize obesity and Type-2 diabetes treatments by mimicking natural gut hormones to suppress appetite and control blood sugar. Despite profound cardiometabolic benefits, rapid weight loss triggers adverse effects, prompting strict global regulatory crackdowns against unauthorized usage.
Click to View MoreThe U.S. move to tariffs on pharmaceuticals, while sparing generics for now, injects uncertainty into India’s pharma industry. This tariff shock highlights overdependence on the U.S. market and Chinese APIs, pushing India to fast-track Atmanirbhar Bharat through PLI schemes and bulk drug parks to secure its future as the world’s pharmacy.
Click to View More
© 2026 iasgyan. All right reserved
